PT  - JOURNAL ARTICLE
AU  - Marc Michel
AU  - Cristophe Duvoux
AU  - Cristophe Hezode
AU  - Daniel Cherqui
TI  - Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease.
DP  - 2003 Jul 01
TA  - The Journal of Rheumatology
PG  - 1624--1625
VI  - 30
IP  - 7
4099  - http://www.jrheum.org/content/30/7/1624.short
4100  - http://www.jrheum.org/content/30/7/1624.full
SO  - J Rheumatol2003 Jul 01; 30
AB  - Infliximab, a chimeric anti-tumor necrosis factor-alpha monoclonal antibody, has been demonstrated to be efficient and safe in patients with active rheumatoid arthritis and in the management of severe bouts of Crohn's disease. However, the safety of infliximab has not been evaluated in patients infected with hepatitis B virus. We report the case of a 28-year-old woman, with a positive hepatitis B virus surface antigen, who developed fulminant hepatitis 2 weeks after receiving a second infliximab infusion for a refractory adult onset Still's disease.